Stairs instead of elevators at the workplace decreases PCSK9 levels in a healthy population

European Journal of Clinical Investigation

Volumn 45, Issue 10, 2015, Pages 1017-1024

  Kamani, Christel H ^a   Gencer, Baris ^a   Montecucco, Fabrizio ^a,b   Courvoisier, Delphine ^c   Vuilleumier, Nicolas ^a   Meyer, Philippe ^a   Mach, François ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY OF GENOA   (Italy)

^c UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

Biomarkers; Lifestyle intervention; Lipids; PCSK9; Physical exercise

Indexed keywords

ADIPONECTIN; ANTILIPEMIC AGENT; APOLIPOPROTEIN B100; C REACTIVE PROTEIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HUMAN INSULIN; INSULIN; LIPOCORTIN 2; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; SERINE PROTEINASE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; PCSK9 PROTEIN, HUMAN;

ADULT; AEROBIC CAPACITY; ANTHROPOMETRIC PARAMETERS; ARTICLE; BODY MASS; BUILDING; CLINICAL ASSESSMENT; CONTROLLED STUDY; EXERCISE; FEMALE; HEALTH PROMOTION; HOSPITAL PERSONNEL; HUMAN; HUMAN EXPERIMENT; INSULIN SENSITIVITY; INTERVENTION STUDY; LIFESTYLE MODIFICATION; MALE; NORMAL HUMAN; OCCUPATIONAL HEALTH; PHYSICAL ACTIVITY; PHYSICAL PERFORMANCE; POPULATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; STAIRS; WORKPLACE; METABOLISM; MIDDLE AGED; PHYSIOLOGY;

ADULT; BIOMARKERS; ELEVATORS AND ESCALATORS; EXERCISE; FEMALE; HEALTHY VOLUNTEERS; HUMANS; MALE; MIDDLE AGED; PROPROTEIN CONVERTASES; SERINE ENDOPEPTIDASES; WORKPLACE;

EID: 84941992948     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/eci.12480     Document Type: Article

References (32)

1. Eckel RH, Jakicic JM, Ard JD, de Jesus JM, Houston Miller N, Hubbard VS et al. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014;129(25 Suppl 2):S76-99.
2. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014;129(25 Suppl 2):S1-45.
3. Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011;32:1769-818.
4. Meyer P, Kayser B, Kossovsky MP, Sigaud P, Carballo D, Keller PF et al. Stairs instead of elevators at workplace: cardioprotective effects of a pragmatic intervention. Eur J Cardiovasc Prev Rehabil 2010;17:569-75.
5. Thompson PD, Buchner D, Pina IL, Balady GJ, Williams MA, Marcus BH et al. Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease: a statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity). Circulation 2003;107:3109-16.
6. Lian XQ, Zhao D, Zhu M, Wang ZM, Gao W, Zhao H et al. The influence of regular walking at different times of day on blood lipids and inflammatory markers in sedentary patients with coronary artery disease. Prev Med 2014;58:64-9.
7. Martins RA, Verissimo MT, Coelho e Silva MJ, Cumming SP, Teixeira AM. Effects of aerobic and strength-based training on metabolic health indicators in older adults. Lipids Health Dis 2010;9:76.
8. Kotseva K, Wood D, De Backer G, De Bacquer D, Pyorala K, Keil U. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil 2009;16:121-37.
9. Vogel RA. PCSK9 inhibition: the next statin? J Am Coll Cardiol 2012;59:2354-5.
10. Mayne J, Dewpura T, Raymond A, Bernier L, Cousins M, Ooi TC et al. Novel loss-of-function PCSK9 variant is associated with low plasma LDL cholesterol in a French-Canadian family and with impaired processing and secretion in cell culture. Clin Chem 2011;57:1415-23.
11. Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 2006;354:1264-72.
12. Abifadel M, Varret M, Rabes JP, Allard D, Ouguerram K, Devillers M et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 2003;34:154-6.
13. Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HN, Masana L, Descamps OS et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J 2013;34:3478-90a.
14. Hovingh GK, Davidson MH, Kastelein JJ, O'Connor AM. Diagnosis and treatment of familial hypercholesterolaemia. Eur Heart J 2013;34:962-71.
15. Ly K, Saavedra YG, Canuel M, Routhier S, Desjardins R, Hamelin J et al. Annexin A2 reduces PCSK9 protein levels via a translational mechanism and interacts with the M1 and M2 domains of PCSK9. J Biol Chem 2014;289:17732-46.
16. Tiwari V, Khokhar M. Mechanism of action of anti-hypercholesterolemia drugs and their resistance. Eur J Pharmacol 2014;741C:156-70.
17. Dias CS, Shaywitz AJ, Wasserman SM, Smith BP, Gao B, Stolman DS et al. Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins. J Am Coll Cardiol 2012;60:1888-98.
18. Raal F, Scott R, Somaratne R, Bridges I, Li G, Wasserman SM et al. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the reduction of LDL-C with PCSK9 inhibition in heterozygous familial hypercholesterolemia disorder (RUTHERFORD) randomized trial. Circulation 2012;126:2408-17.
19. Sullivan D, Olsson AG, Scott R, Kim JB, Xue A, Gebski V et al. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. JAMA 2012;308:2497-506.
20. Koren MJ, Scott R, Kim JB, Knusel B, Liu T, Lei L et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study. Lancet 2012;380:1995-2006.
21. Giugliano RP, Desai NR, Kohli P, Rogers WJ, Somaratne R, Huang F et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study. Lancet 2012;380:2007-17.
22. Arsenault BJ, Pelletier-Beaumont E, Almeras N, Tremblay A, Poirier P, Bergeron J et al. PCSK9 levels in abdominally obese men: association with cardiometabolic risk profile and effects of a one-year lifestyle modification program. Atherosclerosis 2014;236:321-6.
23. Simera I, Moher D, Hoey J, Schulz KF, Altman DG. A catalogue of reporting guidelines for health research. Eur J Clin Invest 2010;40:35-53.
24. Hamer M, Sabia S, Batty GD, Shipley MJ, Tabak AG, Singh-Manoux A et al. Physical activity and inflammatory markers over 10 years: follow-up in men and women from the Whitehall II cohort study. Circulation 2012;126:928-33.
25. Jarvie JL, Whooley MA, Regan MC, Sin NL, Cohen BE. Effect of physical activity level on biomarkers of inflammation and insulin resistance over 5 years in outpatients with coronary heart disease (from the Heart and Soul Study). Am J Cardiol 2014;114:1192-7.
26. Rescher U, Gerke V. Annexins-unique membrane binding proteins with diverse functions. J Cell Sci 2004;117(Pt 13):2631-9.
27. Mayer G, Poirier S, Seidah NG. Annexin A2 is a C-terminal PCSK9-binding protein that regulates endogenous low density lipoprotein receptor levels. J Biol Chem 2008;283:31791-801.
28. Seidah NG, Poirier S, Denis M, Parker R, Miao B, Mapelli C et al. Annexin A2 is a natural extrahepatic inhibitor of the PCSK9-induced LDL receptor degradation. PLoS ONE 2012;7:e41865.
29. Awan Z, Dubuc G, Faraj M, Dufour R, Seidah NG, Davignon J et al. The effect of insulin on circulating PCSK9 in postmenopausal obese women. Clin Biochem 2014;47:1033-9.
30. Richard C, Couture P, Desroches S, Benjannet S, Seidah NG, Lichtenstein AH et al. Effect of the Mediterranean diet with and without weight loss on surrogate markers of cholesterol homeostasis in men with the metabolic syndrome. Br J Nutr 2012;107:705-11.
31. Levy E, Ben Djoudi Ouadda A, Spahis S, Sane AT, Garofalo C, Grenier E et al. PCSK9 plays a significant role in cholesterol homeostasis and lipid transport in intestinal epithelial cells. Atherosclerosis 2013;227:297-306.
32. Rashid S, Tavori H, Brown PE, Linton MF, He J, Giunzioni I et al. Proprotein convertase subtilisin kexin type 9 promotes intestinal overproduction of triglyceride-rich apolipoprotein B lipoproteins through both low-density lipoprotein receptor-dependent and -independent mechanisms. Circulation 2014;130:431-41.